<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZINGO- lidocaine hydrochlorideÂ powderÂ </strong><br>Anesiva, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">Zingoâ„¢ (lidocaine hydrochloride monohydrate powder intradermal injection system)</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<ul class="Disc"><li>Zingoâ„¢Â  is an amide local anesthetic indicated for use on intact skin to provide local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> prior to venipuncture or peripheral intravenous cannulation in children 3â€“18 years of age.Â (<a href="#_1_Indications_and">1</a>)</li></ul>
<p class="Highlighta">Important Limitations: </p>
<ul class="Disc">
<li>For use on intact skin only (<a href="#_1_Indications_and">1</a>,<a href="#_2_Dosage_and">2</a>)<br>
</li>
<li>For external use only (<a href="#_5_Warnings_and">5</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Apply one Zingoâ„¢ (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion. (<a href="#_2_1_Instructions_for">2.1</a>)<br>
</li>
<li>Perform the procedure within 10 minutes after Zingoâ„¢ administration. (<a href="#_2_Dosage_and">2</a>)<br>
</li>
<li>Use Zingoâ„¢ only on intact skin. (<a href="#_2_Dosage_and">2</a>)</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Zingoâ„¢ is a sterile, single-use,Â powderÂ intradermal injectionÂ system containing 0.5Â mg lidocaine hydrochloride monohydrate. (<a href="#_3_Dosage_Forms">3</a>) Â Zingoâ„¢ utilizes a helium-powered delivery system. (<a href="#_11_Description">11</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Zingoâ„¢ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. (<a href="#_4_Contraindications">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Use on intact skin only (<a href="#_2_1_Instructions_for">2.1</a>, <a href="#_5_Warnings_and">5</a>)<br>
</li>
<li>Avoid contact with the eye (<a href="#_2_1_Instructions_for">2.1</a>, <a href="#_5_Warnings_and">5</a>)<br>
</li>
<li>Do not use if device is dropped or the pouch is damaged or tornÂ (<a href="#_2_1_Instructions_for">2.1</a>)<br>
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">platelet disorders</span> could have a higher risk of superficial dermal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#_5_Warnings_and">5</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (&gt;5%) areÂ <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> at the site of administration: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.Â (<a href="#_6_1_Clinical_Trials">6.1</a>) </p>
<p class="Highlighta">Â  </p>
<p class="Highlighta"><br><span class="Bold">Â Â Â Â Â Â Â Â Â Â </span><span class="Bold">Revised:  </span><span class="Bold">April 2008</span> </p>
</div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2008</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc"><span class="Bold">1</span><span class="Bold">Â Â Â Â Â 
	INDICATIONS AND USAGE</span></a></h1>
<h1><a href="#section-3" class="toc"><span class="Bold">2</span><span class="Bold">Â Â Â Â Â 
	DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-3.1" class="toc"><span class="Bold">2.1</span><span class="Bold">Â Â Â Â Â 
	Instructions for Use</span></a></h2>
<h1><a href="#section-4" class="toc"><span class="Bold">3</span><span class="Bold">Â Â Â Â Â 
	DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">4</span><span class="Bold">Â Â Â Â Â 
	CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-6" class="toc"><span class="Bold">5</span><span class="Bold">Â Â Â Â Â 
	WARNINGS AND PRECAUTIONS</span></a></h1>
<h1><a href="#section-7" class="toc"><span class="Bold">6</span><span class="Bold">Â Â Â Â Â 
	ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">6.1</span><span class="Bold">Â Â Â Â Â 
	Clinical Trials Experience</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold">Â Â Â Â Â 
	USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1</span><span class="Bold">Â Â Â Â Â 
	Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2</span><span class="Bold">Â Â Â Â Â 
	Labor and Delivery</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.3</span><span class="Bold">Â Â Â Â Â 
	Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.4</span><span class="Bold">Â Â Â Â Â 
	Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.5</span><span class="Bold">Â Â Â Â Â 
	Geriatric Use</span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">9</span><span class="Bold">Â Â Â Â Â 
	DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">10</span><span class="Bold">Â Â Â Â Â 
	OVERDOSAGE</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">11</span><span class="Bold">Â Â Â Â Â 
	DESCRIPTION</span></a></h1>
<h1><a href="#section-12" class="toc"><span class="Bold">12</span><span class="Bold">Â Â Â Â Â 
	CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">12.1</span><span class="Bold">Â Â Â Â Â 
	Mechanism of Action</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">12.2</span><span class="Bold">Â Â Â Â Â 
	Pharmacodynamics</span></a></h2>
<h2><a href="#section-12.3" class="toc"><span class="Bold">12.</span><span class="Bold">3</span><span class="Bold">Â Â Â Â Â 
	Pharmacokinetics</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">13</span><span class="Bold">Â Â Â Â Â 
	NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">13.1</span><span class="Bold">Â Â Â Â Â 
	Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">14</span><span class="Bold">Â Â Â Â Â 
	CLINICAL STUDIES</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">16</span><span class="Bold">Â Â Â Â Â 
	HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-16" class="toc"><span class="Bold">17</span><span class="Bold">Â Â Â Â Â 
	PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_1_Indications_and"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold">Â Â Â Â Â 
	INDICATIONS AND USAGE</span>
</h1>
<p class="First">Zingoâ„¢ is indicated for use on intact skin to provideÂ topicalÂ local <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> prior to venipuncture orÂ peripheralÂ intravenous cannulation, in children 3-18 years of age.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2_Dosage_and"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">Â Â Â Â Â 
	DOSAGE AND ADMINISTRATION</span>
</h1>
<p class="First">Apply one Zingoâ„¢Â (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion.</p>
<p>Perform the procedure within 10 minutes after Zingoâ„¢ administration.</p>
<p>Use Zingoâ„¢ only on intact skin.</p>
<p>Application of one additional Zingoâ„¢ at a new location is acceptable after a failed attempt at venous access.  Multiple administrations of Zingoâ„¢ at the same location are not recommended.</p>
<p>When Zingoâ„¢ is used concomitantly with other products containing local anesthetic agents, the amount absorbed from all sources should be considered, as local anesthetics are thought to have at least additive toxicities.</p>
<div class="Section">
<a name="_2_1_Instructions_for"></a><a name="section-3.1"></a><p></p>
<h2>
<span class="Bold">2.1</span><span class="Bold">Â Â Â Â Â 
	Instructions for Use</span>
</h2>
<table>
<col width="16">
<col width="168">
<col width="167">
<col width="1">
<thead><tr class="First Last">
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule" valign="top">
<span class="Underline"><br><br>Prepare the Treatment Site and Device</span>:  Examine the treatment site to ensure that the skin is intact.  Clean the site, according to standard practice.<br><br>Visually inspect the pouch.  DoÂ not use if the pouch has been torn, or damaged or if the device has been dropped.<br><br>Tear open the pouch using the notch provided (FigureÂ 1a).  Remove Zingoâ„¢ from the pouch, being careful not to touch the purple outlet (open end) to avoid contamination (FigureÂ 1b).<br>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Figure 1a</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-01.jpg"><br><span class="Bold">Figure 1b</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-02.jpg">
</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule" valign="top">
<br><br><span class="Underline"><br><br><br><br>Position Zingoâ„¢</span>:  Grip Zingoâ„¢  and place on the application site, with one hand, as illustrated in FigureÂ 2, or with both hands, as shown in Figure 3.<br>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Figure 2</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-03.jpg"><br><span class="Bold">Figure 3</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-04.jpg">
</td>
</tr>
<tr>
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule">Ensure that the patientâ€™s treatment site is supported to prevent movement.  Seal the purple Zingoâ„¢ outlet against the patientâ€™s skin.  Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.<br><br>Avoid gaps between the skin and the Zingoâ„¢ outlet, like the one illustrated in FigureÂ 4, as gaps will impede drug delivery.</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Figure 4</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-05.jpg"><br>
</td>
</tr>
<tr>
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule">
<span class="Underline">Release the Safety Interlock</span>:  Apply adequate downward pressure to release the safety interlock, while maintaining the seal between Zingoâ„¢ and the skin.<br><br>Zingoâ„¢ is ready for administration when the green start button has moved into the upward position, as illustrated in FigureÂ 5a.<br>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">
<span class="Bold">Figure 5a</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-06.jpg">
</td>
</tr>
<tr>
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule" colspan="2">
<br>Zingoâ„¢ cannot be actuated without releasing the internal safety interlock, as illustrated in Figure 5b.<br>
</td>
</tr>
<tr>
<td class="Lrule"></td>
<td class="Rrule" align="center" colspan="2">
<span class="Bold">Figure </span><span class="Bold">5b</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-07.jpg">
</td>
</tr>
<tr>
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule">
<br><span class="Underline">Administer Zingo</span><span class="Underline">â„¢</span>:  While maintaining downward pressure, administer the dose by pressing the green start button, as illustrated in FigureÂ 6.  DoÂ not move Zingoâ„¢ during administration.  Actuation is accompanied by a â€œpoppingâ€? sound, indicating that the dose has been discharged.<br>
</td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold">Figure 6</span><br><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-08.jpg">
</td>
</tr>
<tr>
<td class="Lrule Toprule"></td>
<td class="Toprule">
<span class="Underline">Remove Zingoâ„¢</span>: Remove Zingo from the application site and dispose.<br>
</td>
<td class="Rrule Toprule"></td>
</tr>
<tr class="Last">
<td class="Lrule Toprule"></td>
<td class="Rrule Toprule" colspan="2">
<span class="Underline">Begin Procedure</span>:  Start the venipuncture or intravenous cannulation procedure 1â€“3Â minutes after Zingoâ„¢ administration.<span class="Bold">Â </span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3_Dosage_Forms"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">3</span><span class="Bold">Â Â Â Â Â 
	DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">Zingoâ„¢Â (lidocaine hydrochloride monohydrate)Â powder intradermal injectionÂ system<span class="Bold">Â </span>contains 0.5 mg of sterile lidocaine hydrochloride monohydrate.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4_Contraindications"></a><a name="section-5"></a><p></p>
<h1>
<span class="Bold">4</span><span class="Bold">Â Â Â Â Â 
	CONTRAINDICATIONS</span>
</h1>
<p class="First">Zingoâ„¢ is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="_5_Warnings_and"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">5</span><span class="Bold">Â Â Â Â Â 
	WARNINGS AND PRECAUTIONS</span>
</h1>
<p class="First">Do not use around the eyes.</p>
<p>Do not use Zingoâ„¢ on body orifices, mucous membranes, or on areas with a compromised skin barrier.  Only useÂ Zingoâ„¢ on skin locations where an adequate seal can be maintained.</p>
<p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or <span class="product-label-link" type="condition" conceptid="4101133" conceptname="Pseudocholinesterase deficiency">pseudocholinesterase deficiency</span>, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations of lidocaine.</p>
<p>Patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or <span class="product-label-link" type="condition" conceptid="4332151" conceptname="Platelet disorder">platelet disorders</span> could have a higher risk of superficial dermal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>
<span class="Bold">6</span><span class="Bold">Â Â Â Â Â 
	ADVERSE REACTIONS</span>
</h1>
<div class="Section">
<a name="_6_1_Clinical_Trials"></a><a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">6.1</span><span class="Bold">Â Â Â Â Â 
	Clinical Trials Experience</span>
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety of Zingoâ„¢Â was evaluated in fiveÂ randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients,Â ages 3 to 18, received either Zingoâ„¢ or a sham placebo device.  A total of 906 received active treatment, while 855Â received placebo.</p>
<p><span class="Italics">Application S</span><span class="Italics">ite Reaction</span></p>
<p>The application site was specifically assessed for four categories of skin site reaction (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>).  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> occurred in 53% of Zingo-treated patients, and in 27% of placebo-treated patients.  <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> occurred in 44% of Zingo-treated patients, and in 5% of placebo-treated patients.  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> occurred in 8% of Zingo-treated patients, and in 3% of placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> occurred in 1% of patients in both treatment groups.  </p>
<p><span class="Italics">Adverse </span><span class="Italics">Reactions</span></p>
<p>Amongst the 906Â pediatric patientsÂ receiving active treatment and 855Â pediatric patients receiving sham placebo treatment, the percentage of pediatric patientsÂ with any adverse reactions was approximatelyÂ 9% in each treatment group.</p>
<p>Most adverse reactions were application-site related (i.e., <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, burning, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>), occurring in 4% of pediatric patients in each treatment group.  </p>
<p>The most common systemic adverse reactions were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (2%) and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold">Â Â Â Â Â 
	USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1</span><span class="Bold">Â Â Â Â Â 
	Pregnancy</span>
</h2>
<p class="First">Zingoâ„¢ was not formally evaluated for effects on reproduction.  Significant systemic exposure to lidocaine is not expected under recommended conditions of use of Zingoâ„¢ as lidocaine levels were below the limit of detection in human studies.  LidocaineÂ has been previously tested for reproductive toxicity in animal studies, however.  The following ratios are based on the assumption that the applied dose is completely absorbed through the skin.</p>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects</span></h3>
<p class="First">Pregnancy Category B.  Lidocaine was not teratogenic in rats given subcutaneous doses up to 60 mg/kg [360 mg/m<span class="Sup">2</span> or 1200-fold the single dermal administration (SDA) of 0.5Â mg lidocaine in a 60 kg individual (0.3 mg/m<span class="Sup">2</span>)] or in rabbits up to 15 mg/kg (180 mg/m<span class="Sup">2</span> or 600-fold the SDA).  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, Zingoâ„¢ should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.1.2"></a><p></p>
<h3><span class="Italics">Nonteratogenic Effects</span></h3>
<p class="First">Lidocaine, containing 1:100,000 epinephrine, at a dose of 6 mg/kg (36 mg/m<span class="Sup">2</span> or 120-foldÂ the SDA) injected into the masseter muscle of the jaw or into the gum of the lower jaw of Long-Evans hooded pregnant rats on gestation day 11 led to <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> in neonatal behavior among offspring.  <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">Developmental delays</span> were observed for negative geotaxis, static righting reflex, visual discrimination response, sensitivity and response to thermal and electrical <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> stimuli, and water maze acquisition.  The <span class="product-label-link" type="condition" conceptid="436077" conceptname="Developmental delay">developmental delays</span> of the neonatal animals were transient with responses becoming comparable to untreated animals later in life.  The clinical relevance of the animal data is uncertain.  No adequate and wellâ€“controlled studies have been conducted in pregnant women.  Because animal studies are not always predictive of human response, Zingoâ„¢ should be used during pregnancy only if the potential benefit justifies risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.2</span><span class="Bold">Â Â Â Â Â 
	Labor and Delivery</span>
</h2>
<p class="First">Lidocaine is not contraindicated in labor and delivery.  In humans, the use of lidocaine for labor conduction <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> has not been associated with an increased incidence of adverse fetal effects either during delivery or during the neonatal period.  Should Zingoâ„¢ be used concomitantly with other products containing lidocaine, total doses contributed by all formulations must be considered.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.3</span><span class="Bold">Â Â Â Â Â 
	Nursing Mothers</span>
</h2>
<p class="First">Lidocaine is excreted into human milk; therefore, caution should be exercised when Zingoâ„¢Â is administered to a nursing mother.  BecauseÂ noÂ plasma concentrations of lidocaine are detected after topical administration of Zingoâ„¢ in recommended doses, the small amount of lidocaine that would be ingested orally by a suckling infant is unlikely to cause adverse effects. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.4</span><span class="Bold">Â Â Â Â Â 
	Pediatric Use</span>
</h2>
<p class="First">Safety and effectiveness in pediatric patients below the age ofÂ 3 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.5</span><span class="Bold">Â Â Â Â Â 
	Geriatric Use</span>
</h2>
<p class="First">Safety and effectiveness in geriatric patients have not been established. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">9</span><span class="Bold">Â Â Â Â Â 
	DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span>
</h1>
<p class="First">Zingoâ„¢ is not known to possess drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold">Â Â Â Â Â 
	OVERDOSAGE</span>
</h1>
<p class="First">In adults following a single administration of Zingoâ„¢ the plasma levels of lidocaine were below the limit of detection (5 ng/mL).  Signs of central nervous system (CNS) toxicity may start at plasma concentrations of lidocaine as low as 1000 ng/mL, and the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> generally increases with increasing plasma levels.  Very high levels of lidocaine can cause <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, decreases in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, total peripheral resistance, and mean arterial pressure, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.  The toxicity of coadministered local anesthetics is thought to be at least additive.  In the absence of massive topical <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or oral ingestion, other etiologies for the clinical effects or overdosage from other sources of lidocaine or other local anesthetics should be considered.  The management of overdosage includes close monitoring, supportive care, and symptomatic treatment.  Dialysis is of negligible value in the treatment of acute overdosage of lidocaine.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="_11_Description"></a><a name="section-11"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold">Â Â Â Â Â 
	DESCRIPTION</span>
</h1>
<p class="First">Zingoâ„¢ (lidocaine hydrochloride monohydrate)Â powder intradermal injectionÂ systemÂ contains 0.5 mg of sterile lidocaine hydrochloride monohydrate.</p>
<p>The chemical name is 2-diethylamino-2',6'-acetoxylidide, monohydrochloride, monohydrate.  TheÂ molecular formula is C<span class="Sub">14</span>H<span class="Sub">22</span>N<span class="Sub">2</span>O Â· HCl Â· H<span class="Sub">2</span>O with a molecular weight of 288.8Â Da.  Lidocaine hydrochloride monohydrate, a local anesthetic of the amide class, has the following structural formula:Â Â </p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0FB7864F-BE1C-4992-A996-556AEF29981F&amp;name=zingo-figure-09.jpg"></div>
<p>Lidocaine hydrochloride monohydrate is freely soluble in water, soluble in alcohol and chloroform, insoluble in ether, and melts at around 74â€“79Â°C.</p>
<p>Zingoâ„¢ is a ready-to-use, sterile, single-use, disposable, needle-free delivery system.  Zingoâ„¢ consists of the following components: a drug reservoir cassette filled with 0.5Â mg lidocaine hydrochloride monohydrate as a powder with aÂ nominal particle size of 40Â Âµm, a pressurized helium gas cylinder, and a safety interlock. The safety interlock prevents inadvertent actuation of the device. Once Zingoâ„¢ is pressed against the skin, the interlock is released, allowing the button to be depressed to actuate the device. A sound similar to that of a popping balloon is emitted at the time Zingoâ„¢ is actuated.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold">Â Â Â Â Â 
	CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">12.1</span><span class="Bold">Â Â Â Â Â 
	Mechanism of Action</span>
</h2>
<p class="First">Zingoâ„¢ delivers lidocaineÂ hydrochloride monohydrate into the dermis.Â Â Lidocaine is an amide-type local anesthetic agent that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">12.2</span><span class="Bold">Â Â Â Â Â 
	Pharmacodynamics</span>
</h2>
<p class="First">Zingoâ„¢ provides local dermal <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> within 1â€“3Â minutes of application.  <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> diminishes within 10 minutes of treatment.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-12.3"></a><p></p>
<h2>
<span class="Bold">12.</span><span class="Bold">3</span><span class="Bold">Â Â Â Â Â 
	Pharmacokinetics</span>
</h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>A singleÂ dose ofÂ Zingoâ„¢ in adultsÂ did not produce detectableÂ plasma concentrationsÂ of lidocaineÂ (limit of quantitation 5Â ng/mL) in any subject tested (n = 38).</p>
<p>Application of Zingoâ„¢ to broken or inflamed skin, or multiple Zingoâ„¢ applications,Â could result in systemic plasma levels of lidocaineÂ that could produce systemic toxicity.</p>
<p><span class="Italics">Distribution</span></p>
<p>When lidocaine is administered intravenously to healthy volunteers, the steady-state volume of distribution is approximately 0.8Â toÂ 1.3Â L/kg.  At much higher plasma concentrations (1Â toÂ 4Â mcg/mL of free base) than those found following application of Zingoâ„¢, the plasma protein binding of lidocaine is concentration dependent.  Lidocaine crosses the placental and blood brain barriers, presumably by passive diffusion.  CNS toxicity may typically be observed around 5000 ng/mLÂ of lidocaine; however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL. </p>
<p><span class="Italics">Metabolism</span></p>
<p>It is not known if lidocaine is metabolized in the skin.  Lidocaine is metabolized rapidly by the liver to a number of metabolites including monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both of which have pharmacologic activity similar to, but less potent than that of lidocaine.  The major metabolic pathway of lidocaine, sequential N-deethylation to monoethylglycinexylidide (MEGX) andÂ glycinexylidide (GX), is primarily mediated by CYP1A2 with a minor role of CYP3A4.  The metabolite, 2,6-xylidine, has unknown pharmacologic activity.  Following intravenous administration of lidocaine, MEGX and GX concentrations inÂ serum range from 11%Â to 36% and from 5% to 11% of lidocaine concentrations, respectively.  Serum concentrations of MEGX are about one-third the serum lidocaine concentrations. </p>
<p><span class="Italics">Elimination</span></p>
<p>The half-life of lidocaine elimination from the plasma following intravenous administration is approximately 1.8 hours.  Lidocaine and its metabolites are excreted by the kidneys.  More than 98% of an absorbed dose of lidocaine can be recovered in the urine as metabolites or parent drug.  Less than 10% of lidocaine is excreted unchanged in adults, and approximately 20% is excreted unchanged in neonates.  The systemic clearance is approximately 8â€“10 mL/min/kg.  During intravenous studies, the elimination half-life of lidocaine was statistically significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours).</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold">Â Â Â Â Â 
	NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">13.1</span><span class="Bold">Â Â Â Â Â 
	Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First"><span class="Italics">Carcinogenesis</span></p>
<p>Long-term studies in animals have not been performed to evaluate the carcinogenic potential of lidocaine.</p>
<p><span class="Italics">Mutagenesis</span></p>
<p>No mutagenic potential of lidocaine was demonstrated in the inÂ vitro Ames Bacterial Reverse Mutation Assay, the in vitro chromosome aberration assay using Chinese hamster ovary cells, and the inÂ vivo mouse micronucleus assay. </p>
<p><span class="Italics">Impairment of Fertility</span></p>
<p>Zingoâ„¢ was not formally evaluated for effects on fertility. Significant systemic exposure to lidocaine is not expected under recommended conditions of use of Zingoâ„¢, as lidocaine levels were below the limit of detection in human studies. Lidocaine has been previously tested in animal studies for effects on fertility, however. The following ratios are based on the assumption that the applied dose is completely absorbed through the skin.</p>
<p>Lidocaine did not affect fertility in female rats when given via continuous subcutaneous infusion via osmotic minipumps up to doses of 250 mg/kg/day [1500 mg/m<span class="Sup">2</span> or 5000-fold higher than the SDA of 0.5 mg lidocaine in a 60 kg individual (0.3 mg/m<span class="Sup">2</span>)].  Although lidocaine treatment of male rats increased the copulatory interval and led to a dose-related decreased homogenization resistant sperm head count, daily sperm production, and spermatogenic efficiency, the treatment did not affect overall fertility in male rats when given subcutaneous doses up to 60 mg/kg (360 mg/m<span class="Sup">2</span> orÂ 1200-fold the SDA).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold">Â Â Â Â Â 
	CLINICAL STUDIES</span>
</h1>
<p class="First"><span class="Italics">Efficacy in Pediatric Patients</span></p>
<p>The efficacy of Zingoâ„¢ in patientsÂ 3â€“18 yearsÂ of ageÂ was evaluated in 2Â randomized, double-blind, parallel-arm, sham-placebo controlled trials in which pediatric patientsÂ received either Zingoâ„¢ or a sham placebo device.</p>
<p>The overall patient population consisted of healthy pediatric patients as well as those with acute and chronic medical conditions (i.e.,Â <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder, <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> and renal or hepatic transplantation) ages 3â€“18Â years.  All patients required peripheral venipuncture or intravenous cannulation as part of their clinical care.</p>
<p>Two efficacyÂ trials (Studies 1 and 2) were conductedÂ during which patients were treated with Zingoâ„¢ or aÂ placebo device at the back of hand or antecubital fossa, between one and three minutes prior to venipuncture or peripheral venous cannulation.  Measurements of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> were made immediately following the venous procedure.  Efficacy was measured using a modified version of the Wong-Baker FACES <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> rating scale [aÂ categorical 6-point scale containing 6Â faces ranging from 0Â (â€œno hurtâ€?) to 5Â (â€œhurtsÂ worstâ€?)].</p>
<p>In both studies, treatment with active drug resulted inÂ less <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>,Â from venipuncture or peripheral IV cannulation, compared with placebo (See Table 1).</p>
<table>
<caption><span>Table 1:  Modified FACES Scale Score (ITTÂ Population), StudiesÂ 1 andÂ 2</span></caption>
<col width="95">
<col width="68">
<col width="68">
<col width="64">
<col width="72">
<thead><tr class="First Last">
<td class="Toprule"></td>
<td class="Toprule" align="center" colspan="2">
<span class="Bold">Â </span><span class="Bold">Â Â Â </span><span class="Bold">Â Â Â Â Â Â Â </span><span class="Bold">Study</span><span class="Bold">Â </span><span class="Bold">1</span><span class="Bold">Â Â Â Â Â Â Â </span><span class="Bold">Â Â Â Â Â </span>
</td>
<td class="Toprule" align="center" colspan="2">
<span class="Bold">Â Â Â Â Â Â </span><span class="Bold">Â Â Â Â Â Â Â Â </span><span class="Bold">Study</span><span class="Bold">Â </span><span class="Bold">2</span><span class="Bold">Â Â Â Â Â Â </span><span class="Bold">Â Â Â Â Â Â Â </span>
</td>
</tr></thead>
<tbody>
<tr class="First">
<td></td>
<td align="center">
<span class="Bold">Active</span><br><span class="Bold">(N = 292)</span>
</td>
<td align="center">
<span class="Bold">Placebo</span><br><span class="Bold">(</span><span class="Bold">N = 287)</span>
</td>
<td align="center">
<span class="Bold">Â Active</span><br><span class="Bold">Â (N = 269</span><span class="Bold">)</span>
</td>
<td align="center">
<span class="Bold">PlaceboÂ Â </span><br><span class="Bold">(N = 266)Â Â </span>
</td>
</tr>
<tr>
<td>Adjusted MeanÂ <br>LSM<span class="Sup">1</span>Â </td>
<td align="center">1.77</td>
<td align="center">2.10</td>
<td align="center">Â 1.38</td>
<td align="center">1.77Â Â </td>
</tr>
<tr>
<td>Difference in LSMs (SE<span class="Sup">2</span>)</td>
<td align="center" colspan="2">-0.33 (0.13)</td>
<td align="center" colspan="2">-0.39 (0.13)</td>
</tr>
<tr>
<td>95% Confidence Limits</td>
<td align="center" colspan="2">-0.58, -0.08</td>
<td align="center" colspan="2">-0.65, -0.13</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="5">
<br><span class="Sup">1</span>least squares mean<br><span class="Sup">2</span>standard error</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold">Â Â Â Â Â 
	HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">NDCÂ 28000-105-12  Â Zingoâ„¢Â (lidocaine hydrochloride monohydrate)Â powder intradermal injectionÂ systemÂ contains 0.5Â mg of sterile lidocaine hydrochloride monohydrate. Zingoâ„¢ is a single-use device packaged in an individual foil/clear pouch placed inside aÂ bubble-wrap sleeve.  Twelve sleevesÂ are placed in labeled cartons.</p>
<p>Cartons are stored at controlled room temperature (15â€“30Â°C, 59â€“86Â°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>
<span class="Bold">17</span><span class="Bold">Â Â Â Â Â 
	PATIENT COUNSELING INFORMATION</span>
</h1>
<p class="First">Patients should be made aware that a soundÂ similar to that of a popping balloonÂ is emitted at the time Zingoâ„¢ isÂ actuated.</p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> includingÂ <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and edemaÂ may occur.</p>
<p><br><br>Manufactured by:<br>Anesiva, Inc.<br>South San Francisco, CA 94080</p>
<p><br>Distributed by:<br>Sagent Pharmaceuticals, Inc.<br>Schaumburg, IL 60195</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZINGOÂ 		
					</strong><br><span class="contentTableReg">lidocaine hydrochloride powder</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:28000-105</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRADERMAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>lidocaine hydrochloride</strong> (lidocaine) </td>
<td class="formItem"></td>
<td class="formItem">0.5Â mg</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:28000-105-12</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Anesiva, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>367590AF-703B-2FFD-8E43-B1AA5165A735</div>
<div>Set id: 0FB7864F-BE1C-4992-A996-556AEF29981F</div>
<div>Version: 2</div>
<div>Effective Time: 20080625</div>
</div>
</div>Â <div class="DistributorName">Anesiva, Inc.</div></p>
</body></html>
